Tiago Fauth
Stock Analyst at Wells Fargo
(3.19)
# 1,217
Out of 5,099 analysts
152
Total ratings
43.97%
Success rate
2.63%
Average return
Main Sectors:
Stocks Rated by Tiago Fauth
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Maintains: Overweight | $171 → $217 | $189.85 | +14.30% | 9 | Oct 31, 2025 | |
| WVE Wave Life Sciences | Maintains: Overweight | $21 → $18 | $20.23 | -11.02% | 4 | Sep 4, 2025 | |
| UTHR United Therapeutics | Maintains: Equal-Weight | $295 → $414 | $484.86 | -14.61% | 7 | Sep 3, 2025 | |
| MNKD MannKind | Maintains: Overweight | $9 → $10 | $5.84 | +71.23% | 2 | Sep 3, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $79 → $73 | $74.10 | -1.48% | 5 | Aug 20, 2025 | |
| LQDA Liquidia | Maintains: Overweight | $25 → $31 | $32.68 | -5.14% | 3 | Aug 13, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $333 → $395 | $404.46 | -2.34% | 7 | Aug 1, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $88 → $65 | $36.00 | +80.56% | 8 | Jul 10, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $67 → $76 | $72.70 | +4.54% | 1 | Jun 30, 2025 | |
| SVRA Savara | Maintains: Overweight | $8 → $7 | $6.69 | +4.63% | 2 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $112 → $101 | $20.16 | +401.12% | 4 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $3 | $1.28 | +134.38% | 2 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $26 | $21.84 | +19.05% | 6 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $17 | $9.85 | +72.59% | 1 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $75 | $92.85 | -19.22% | 1 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $62 | $8.69 | +613.46% | 5 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $89 | $201.24 | -55.77% | 16 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $51 | $32.60 | +56.44% | 3 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $120 | $53.70 | +123.46% | 7 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $4 | $23.56 | -83.02% | 4 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $3.97 | +252.64% | 4 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $300 | $85.67 | +250.18% | 5 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $26 | $10.74 | +142.09% | 5 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $28 | $3.77 | +642.71% | 7 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $81 | $24.68 | +228.20% | 11 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8 | $0.77 | +933.99% | 5 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $4.29 | +226.34% | 2 | Mar 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $38 → $34 | $1.54 | +2,107.79% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $150 | $29.45 | +409.34% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $41.07 | -29.39% | 1 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $2.00 | +550.00% | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $13 | $2.60 | +400.00% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $2.5 → $2 | $1.05 | +90.48% | 4 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $297 → $340 | $890.11 | -61.80% | 3 | Dec 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $265 → $259 | $315.38 | -17.88% | 1 | Apr 28, 2021 |
Insmed
Oct 31, 2025
Maintains: Overweight
Price Target: $171 → $217
Current: $189.85
Upside: +14.30%
Wave Life Sciences
Sep 4, 2025
Maintains: Overweight
Price Target: $21 → $18
Current: $20.23
Upside: -11.02%
United Therapeutics
Sep 3, 2025
Maintains: Equal-Weight
Price Target: $295 → $414
Current: $484.86
Upside: -14.61%
MannKind
Sep 3, 2025
Maintains: Overweight
Price Target: $9 → $10
Current: $5.84
Upside: +71.23%
PTC Therapeutics
Aug 20, 2025
Maintains: Overweight
Price Target: $79 → $73
Current: $74.10
Upside: -1.48%
Liquidia
Aug 13, 2025
Maintains: Overweight
Price Target: $25 → $31
Current: $32.68
Upside: -5.14%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Equal-Weight
Price Target: $333 → $395
Current: $404.46
Upside: -2.34%
Ultragenyx Pharmaceutical
Jul 10, 2025
Maintains: Overweight
Price Target: $88 → $65
Current: $36.00
Upside: +80.56%
BridgeBio Pharma
Jun 30, 2025
Maintains: Overweight
Price Target: $67 → $76
Current: $72.70
Upside: +4.54%
Savara
May 28, 2025
Maintains: Overweight
Price Target: $8 → $7
Current: $6.69
Upside: +4.63%
Mar 21, 2025
Maintains: Overweight
Price Target: $112 → $101
Current: $20.16
Upside: +401.12%
Mar 4, 2025
Maintains: Equal-Weight
Price Target: $4 → $3
Current: $1.28
Upside: +134.38%
Feb 27, 2025
Maintains: Overweight
Price Target: $28 → $26
Current: $21.84
Upside: +19.05%
Feb 20, 2025
Maintains: Overweight
Price Target: $18 → $17
Current: $9.85
Upside: +72.59%
Aug 22, 2024
Initiates: Overweight
Price Target: $75
Current: $92.85
Upside: -19.22%
Aug 11, 2023
Maintains: Outperform
Price Target: $63 → $62
Current: $8.69
Upside: +613.46%
Jun 14, 2023
Assumes: Neutral
Price Target: $89
Current: $201.24
Upside: -55.77%
Jun 14, 2023
Assumes: Outperform
Price Target: $51
Current: $32.60
Upside: +56.44%
Jun 14, 2023
Assumes: Outperform
Price Target: $120
Current: $53.70
Upside: +123.46%
May 23, 2023
Reiterates: Underperform
Price Target: $4
Current: $23.56
Upside: -83.02%
May 16, 2023
Reiterates: Outperform
Price Target: $14
Current: $3.97
Upside: +252.64%
May 16, 2023
Reiterates: Outperform
Price Target: $300
Current: $85.67
Upside: +250.18%
May 11, 2023
Reiterates: Outperform
Price Target: $26
Current: $10.74
Upside: +142.09%
May 5, 2023
Maintains: Outperform
Price Target: $34 → $28
Current: $3.77
Upside: +642.71%
May 5, 2023
Maintains: Neutral
Price Target: $70 → $81
Current: $24.68
Upside: +228.20%
Mar 24, 2023
Reiterates: Neutral
Price Target: $8
Current: $0.77
Upside: +933.99%
Mar 23, 2023
Reiterates: Outperform
Price Target: $14
Current: $4.29
Upside: +226.34%
Mar 10, 2023
Maintains: Outperform
Price Target: $38 → $34
Current: $1.54
Upside: +2,107.79%
Mar 10, 2023
Reiterates: Outperform
Price Target: $150
Current: $29.45
Upside: +409.34%
Jan 26, 2023
Initiates: Outperform
Price Target: $29
Current: $41.07
Upside: -29.39%
Dec 16, 2022
Initiates: Outperform
Price Target: $13
Current: $2.00
Upside: +550.00%
Nov 18, 2022
Downgrades: Neutral
Price Target: $25 → $13
Current: $2.60
Upside: +400.00%
May 13, 2022
Maintains: Underperform
Price Target: $2.5 → $2
Current: $1.05
Upside: +90.48%
Dec 20, 2021
Maintains: Neutral
Price Target: $297 → $340
Current: $890.11
Upside: -61.80%
Apr 28, 2021
Maintains: Outperform
Price Target: $265 → $259
Current: $315.38
Upside: -17.88%